retatrutide sequence an amino acid sequence - Retatrutidecas Number retatrutide Unraveling the Retatrutide Sequence: A Deep Dive into a Novel Triple Agonist

Retatrutidechemical Name The retatrutide sequence represents a significant advancement in the development of therapeutic peptides, particularly for metabolic disordersRetatrutide (LY3437943) is a triple peptidic agonist of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon .... This complex molecule, also identified by its CAS number 2381089-83-2, is a synthetic peptide with a remarkable structure and a tripartite mechanism of action.Retatrutide Understanding its retatrutidechemical sequence is crucial for appreciating its biological activity and potential pharmaceutical applications.

At its core, retatrutide is an oligopeptide, a chain of amino acids. Various sources provide slightly different representations of this retatrutidepeptide sequence, often due to variations in notation for non-standard amino acids and specific modifications.Retatrutide - KEGG DRUG However, a widely accepted depiction of the amino acid sequence is YA¹QGTFTSDYSL²LDKKAQA¹AFIEYLLEGGPSSGAPPPS³.Compound: RETATRUTIDE (CHEMBL5095485) - ChEMBL Another detailed representation is YXQGTFTSDY SILLDKKAQX AFIEYLLEGG PSSGAPPPS.RETATRUTIDE The retatrutidechemical name itself hints at its complexity, and the retatrutidepeptide structure allows it to interact with multiple hormone receptors.

The retatrutide (LY3437943) molecule is characterized by not only its primary amino acid arrangement but also by the inclusion of non-coded amino acid residuesRetatrutide - KEGG DRUG. These modifications are key to its enhanced stability and efficacy. Specifically, the retatrutide sequence incorporates non-natural amino acids at specific positions, such as Aib², Aib²⁰, and aMeL¹³.Retatrutide - KEGG DRUG These modified residues contribute to increased stability and are detailed in discussions about retatrutide synthesis. Furthermore, the peptide backbone sequence of Retatrutide contains three non-code amino acid residues at positions 2, 20, and 13, enhancing its overall robustness.Retatrutide; Molecular Formula. C221H342N46O ; Synonyms. Retatrutide; 2381089-83-2; LY3437943; orb1981169; EX-A7826E ; Molecular Weight. 4731 g/mol. Computed by ...

Beyond the amino acid chain, retatrutide is further modified with a C20 fatty diacid moiety. This lipidation is a critical design element, enabling albumin binding.Retatrutide | C221H342N46O68 | CID 171390338 - PubChem This binding prolongs the drug's half-life in the body, leading to less frequent dosing and improved patient complianceC221H342N46O68. Molecular Weight: 4731.33.Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C2.. The retatrutide chemical structure therefore comprises both the peptide sequence and this essential fatty acid appendage, collectively contributing to its pharmacokinetic profile. Information on the retatrutide molecular weight places it at approximately 4731 g/mol or 4731.34, reflecting the substantial size of this complex molecule. Its exact mass is reported as 4728.4718.

The functional significance of the retatrutide sequence lies in its action as a triple agonistRetatrutide (LY3437943) is a triple peptidic agonist of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon .... It targets three key receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R)Synthesis of retatrutide by native chemical ligation (NCL), a .... This simultaneous activation of multiple pathways is a novel approach to managing complex metabolic conditions. The triple agonist activity is a cornerstone of retatrutide's mechanism of action, differentiating it from earlier single or dual agonists like semaglutideChemistry. edit.Retatrutideis a peptide with the following amino acidsequence. YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³. where letters with .... Research into the retatrutide (LY3437943) TFA form, as well as understanding retatrutide (LY3437943), provides further insight into its therapeutic potential.Name. Retatrutide (USAN) ; Formula. C221H342N46O68 ; Exact mass. 4728.4718 ; Mol weight. 4731.34 ; Sequence.YXQGTFTSDY SILLDKKAQX AFIEYLLEGG PSSGAPPPS.

The retatrutide sequence and its modifications are the subject of extensive research and development, including detailed studies on retatrutide synthesis.Retatrutide Various synthetic methodologies are being explored, such as native chemical ligation (NCL), to efficiently produce this complex peptideRetatrutide. Innovations in retatrutide synthesis ensure high purity, with reported purities of 99.4% peptideThe invention is a Retatrutide's synthetic method, this method is through choosing the 17 th site of amino acid of syntheticRetatrutide sequenceas Dde-Lys ( .... The development of this peptide involves intricate chemical processes to assemble the retatrutide sequence with the required precision.2024年8月7日—Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested byretatrutide. ;SequenceAnnotations. Expand.

While specific details on every amino acid might vary slightly in publicly available datasheets, the core retatrutide sequence and its key structural features are well-established. For instance, the peptide backbone sequence of Retatrutide contains three non-code amino acid residues at positions 2, 20, and 13. Such modifications, like the [β-Asp]¹⁵-Retatrutide variant, highlight the ongoing efforts to fine-tune the molecule.☰ ; 35. T → M · Missense. Germline mutation ; 40. R → *. stop gained. Germline mutation ; 40. R → Q · Missense. Germline mutation. The therapeutic target of retatrutide is critically linked to the GIPR and GCGR receptors, along with GLP-1R. The drug's efficacy is a direct consequence of its precisely engineered sequence.Structural insights into the triple agonism at GLP-1R, GIPR ...

In summary, the retatrutide sequence, represented by its complex arrangement of amino acids and strategic non-coded residues, along with its fatty acid modification, underpins its role as a potent triple agonistTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 .... This meticulous design allows retatrutide to target GCGR, GIPR, and GLP-1R receptors, offering a promising new avenue for therapeutic intervention in metabolic diseases. Analytical data, such as its retatrutidemolecular weight, and its detailed exploration in scientific literature solidify its position as a leading candidate in pharmaceutical research, with ongoing investigations into its retatrutide chemical structure and various synthetic pathwaysRetatrutide - Inxight Drugs.